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surgery was obtained. a total of 325 records were include in the study. Appendicitis 
was most common cause of admission (N= 124, 40.6%). Most of the patients (N= 
209, 68.5%) hospitalized for maximum of 4 days in hospitals after surgery. Most 
commonly prescribed antibiotics were Ceftriaxone, Metronidazole and Gentamicin. 
Cases of multiple antibiotic in treatment were high, in which triple antibiotics con-
taining treatments were leading (N= 220, 72%) followed by double antibiotics con-
taining treatments (N= 85, 28%). ConClusions: The study revealed that there was 
high number of antibiotics prescribed to the post operative patients irrationally, as 
there is no evidence for the prescription of these antibiotics. Antibiotics are pre-
scribed in multiple forms. There is strong need of a local Guidelines to be established 
for use of antibiotics rationally.
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objeCtives: China is far behind the international standard in health equity. The 
main purpose of this paper is to evaluate the equity of health services utilization 
of rural residents in western China and analyze its influencing factors, thus raising 
policy suggestions to improve the equity of health system. Methods: Related 
data on health services utilization of rural residents were collected through ran-
dom-sampling household surveys. Based on the standardized variable of Health 
Need, the parallel equity of rural residents’ health service utilization is assessed 
by calculating Concentration Index (CI) and mean-value and difference testing 
among residents of different income levels, while the vertical equity is evalu-
ated by calculating Index of Dissimilarity (ID) among residents of different ages. 
Besides, Two-step Model is adapted to analyze its influencing factors. Results: 
On outpatient service utilization, Standard CI of two-week outpatient visiting 
rate, two-week outpatient visiting times and outpatient expenditure are 0.1048, 
0.1213 and 0.5178 respectively, while ID of the three indexes mentioned above are 
0.054719, 0.056134 and 0.011823 respectively (P< 0.05). On inpatient service utiliza-
tion, Standard CI of annual hospitalization rate, annual hospitalization times, days 
of hospitalization, inpatient expenditure and its compensation level are 0.07914, 
0.0543, -0.098, 0.3012 and 0.1740 respectively, while ID of the five indexes men-
tioned above are 0.053098, 0.06122, 0.308912, 0.316444 and 0.379235 respectively 
(P< 0.05). Health status, financial ability, educational level and marital status have 
significant influence on health service utilization equity. ConClusions: Parallel 
inequity of health service utilization of rural residents of different income lev-
els exits in outpatient expenditure, inpatient expenditure and its compensation 
level, while vertical inequity of rural residents of different ages exits in days of 
hospitalization, inpatient expenditure and its compensation level. Comprehensive 
measures should be considered to alleviate the inequity of health service utiliza-
tion in rural residents who live alone, come from less well-off families and have 
poorer health, lower educational levels.
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objeCtives: Data on health services utilization of urban residents collected 
through random-sampling household surveys are analyzed to access the equity of 
health service utilization of urban residents in western China. Methods: Variable 
of Health Need of urban residents is standardized through Logistic Model, Negative 
Binomial Model and Possion Model. Residents are divided into 5 groups by per 
capita annual income in families, and parallel equity of health service utilization 
is assessed by calculating Concentration Index (CI) and mean-value and difference 
testing among residents of different income levels. While residents are divided into 8 
groups by ages, and vertical equity is evaluated by calculating Index of Dissimilarity 
(ID) among residents of different ages. Results: On outpatient service utilization, 
Standard CI of two-week outpatient visiting rate, two-week outpatient visiting times, 
outpatient expenditure and its compensation level are -0.0040, -0.0115, 0.0244, 0.2356 
respectively, while ID of the four indexes mentioned above are 0.2709 (P< 0.05), 0.3285 
(P< 0.05), 0.3434 (P< 0.05), 0.3785 (P= 0.5489) respectively. On inpatient service utiliza-
tion, Standard CI of annual hospitalization rate, annual hospitalization times, days of 
hospitalization, inpatient expenditure and its compensation level are 0.1110, 0.0200, 
0.0260, 0.0336 and 0.1449 respectively, while ID of the five indexes mentioned above 
are 0.3139, 0.3408, 0.3814, 0.4397, 0.4691 respectively (P< 0.05). ConClusions: Equity 
of outpatient service utilization is poor in that urban residents with low-income or 
over the age of 65 get fewer outpatient compensation fees, while equity of hospitali-
zation service utilization is weak in that low-income urban residents use fewer hos-
pitalization services and get less hospitalization compensation fees, and that urban 
residents over the age of 65, who is in most health service demand, can neither get 
the most hospitalization services nor receive a higher proportion of hospitalization 
compensation. Comprehensive measures should be taken to improve the equity of 
health service utilization in urban residents who are old-aged or come from less 
well-off families.
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objeCtives: The factors which determine health services utilization (HSU) and 
access to health services are at the epicentre of health policy discussions, in an 
and adverse event investigations (14.6%). Foremost cited products were bevaci-
zumab and sorafenib. Sponsorship was independent (43.4%), not reported (28.7%), 
industry (6.6%), or inaccessible at time of assessment (21.3%). Many SLRs were 
from China. ConClusions: In our analysis, PLoS ONE published the most SLRs. 
Journals offering open access are attracting a growing number of SLRs and many 
boast a diverse readership. A significant body of work is emerging from China 
where, as in the rest of the world, the majority of SLRs appear to be independently 
sponsored. SLRs are valued by clinical, payer, and regulatory decision-makers, 
since they provide a convenient synthesis of available evidence to address knowl-
edge gaps and facilitate translation of research into practice.
PHP61
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objeCtives: Few studies have been conducted on vitamin dispensing patterns 
in retail pharmacies in South Africa. The aim of this study was to analyse the dis-
pensing patterns of vitamins (ATC group A11) over a one year period in a group of 
community pharmacies in South Africa. Methods: A retrospective drug utilisa-
tion study was conducted on community pharmacy electronic dispensing records 
in South Africa for 2013. All products in ATC subgroup A11 were extracted and 
analysed. Results: A total of 164 233 vitamin products were dispensed to 84 805 
patients. Most patients were females (62.64%) and most of the vitamin products 
(59.62%) were dispensed to females. Males received on average 2.09 (SD= 2.63) 
vitamin products per year, compared to 1.84 (SD= 2.13) products for females. 
Ergocalciferol (A11CC01) was the most often dispensed (37.48% of all vitamin 
products), followed by plain Vitamin B-complex products (A11EA00) accounting for 
32.77%. Ergocalciferol is only available on prescription in South Africa (50 000 IU tab-
lets or 50 000 IU/ml oily drops). The tablets are relatively inexpensive (approximately 
R2.50 per tablet). Of all the dosage formulations, tablets were preferred (62.84% of 
all vitamin products). Most injections were for Vitamin B1 or Vitamin B combina-
tion products. Vitamin B injections have recently been rescheduled in South Africa 
to prescription-only products and consumers therefore no longer can buy these 
products from a pharmacy or ask the pharmacist to administer a Vitamin B injection 
without a prescription. The number of vitamin products dispensed increased stead-
ily over the year. ConClusions: Vitamins are important in treating nutritional 
deficiencies, yet few studies on vitamins have been conducted in pharmacies. It is 
expected that the change in the over-the-counter availability of Vitamin B injec-
tions in South Africa will impact on their dispensing and usage patterns. It will be 
important to monitor the effect that this change in prescribing status will have on 
vitamin sales in pharmacies.
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objeCtives: Substitution has been implemented for generics in most markets 
and very often resulted in high uptake correlated with fast and strong price ero-
sion. Although biosimilars and generics are different, the low biosimilar penetra-
tion in most of Europe prompted some countries to discuss the implementation 
of substitution for biosimilars as an initiative to quickly reduce healthcare spend-
ing by boosting their uptake. The objective of this study was to identify initiatives 
undertaken worldwide with regards to biosimilar substitution and their potential 
implications. Methods: A literature review was conducted from European and 
national health authorities’ websites, Generics and Biosimilars Initiative website, 
Medline® database, and available grey literature. Results: In Europe, European 
Medicines Agency leaves substitution responsibility to national regulators. Sixteen 
EU Member States have either law or guidelines prohibiting automatic biosimi-
lar substitution. In 2013, France became the first European country to pass a law 
for biosimilar substitution. In 2014, Norwegian government set up a clinical study 
to assess interchangeability of Remicade® (infliximab) and its biosimilar. In the 
United-States, the Food and Drug Administration has the authority to designate a 
biosimilar as interchangeable but substitution is then regulated at state level. Thirty 
one states have currently considered legislation establishing standards for biosimi-
lar substitution. In Canada, interchangeability remains a provincial decision. So far, 
one province positioned against substitution. The Pharmaceutical Benefits Advisory 
Committee in Australia recently considered marking biosimilar as equivalent to 
reference product, which would allow substitution at pharmacy level. In South 
Korea, Japan and South Africa automatic substitution is prohibited at pharmacy 
level. ConClusions: In most countries, the choice of treatment with a reference 
biologic or with a biosimilar remains a clinical decision entrusted to the prescrib-
ing physician. Enhancing substitution may increase the penetration of biosimilars 
which constitutes an additional therapeutic option available to practitioners.
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objeCtives: Present study is conducted to determine the trend and use of antibi-
otics among the post-operative patients of tertiary care hospital. Methods: The 
present study was designed as retrospective study. The data was obtained from 
the records of tertiary care hospital (Bolan Medical complex Hospital). The data 
was gathered randomly from the record for the period between July to October, 
2015. Information regarding antibiotic use along patient related data was obtained. 
The collected data was reviewed, coded, verified and statistically analyzed using 
SPSS. Results: Data from the patients, who has been prescribed antibiotic after 
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objeCtives: Within the National Institute for Health and Care Excellence (NICE) 
Appraisal process, quality adjusted life years (QALYs) are regarded as having equal 
weighting. However, in January 2009, NICE introduced the end-of-life (EOL) crite-
ria, giving more weight to QALYs for life-extending, and EOL interventions. In May 
2014, the Scottish Medicines Consortium (SMC) introduced the Patient and Clinician 
Engagement (PACE) process for evaluating EOL medicines and medicines used to 
treat very rare conditions, to allow a more flexible approach to considering such 
medicines. These two initiatives allow a greater cost per QALY gained willingness-
to-pay threshold than usual in the United Kingdom (UK), however there are differ-
ences in their requirements and outcomes. The aim of this study was to compare 
the process and conclusions drawn by NICE and the SMC for health technology 
appraisal submissions either meeting NICE EOL criteria after May 2014, or being 
accepted into the PACE process based on EOL. Methods: All technologies reviewed 
under the PACE process, NICE EOL criteria or both were identified. Information 
collected included whether EOL criteria were met, incremental cost effectiveness 
ratio (ICER) and SMC and NICE decisions. Results: In total, 15 technologies were 
reviewed. Of the 15, 14 were reviewed under PACE; 8 were given positive SMC Advice, 
3 were given restricted positive SMC Advice and 3 were given negative SMC Advice. 
Of the 14 technologies reviewed under the PACE process, 7 were reviewed by NICE, 
4 met EOL criteria, 2 of which were given positive NICE Guidance. ConClusions: 
Of those technologies considered by both NICE and SMC since May 2014, fewer met 
the NICE EOL criteria than the PACE EOL criteria, and fewer still received positive 
NICE Guidance. There are differences in access to interventions for diseases with 
short life expectancies within the UK, although further research into the changing 
Cancer Drugs Fund is needed.
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objeCtives: To analyse the causes and financial implications of the variabil-
ity of use of A&E resources (visits, admissions) across Spanish Hospitals and 
Regions Methods: Review of the Configuration Management DataBase Set (CMDB) 
and Hospital Discharge Statistics during the period 2010-2012, using a multivari-
ate analyses controlling for factors like: region, sex, age, income, etc. to explain 
the relative rate to average and variations within and between regions. Results: 
There is a significant variation between and within regions and hospitals, which 
is mostly explained by personal income, distance to hospitals, availability of alter-
natives in Primary Care, and, quite interestingly (p< 0.05 within Hospitals of same 
regions), size of hospital measured in terms of available beds. This impacts on the 
resource allocation, new hospitals to be erected -new investments- and cost per 
patient. ConClusions: Variability of A&E resource utilisation (frequency of visits, 
hospitalizations) is greatly explained using a multidimensional approach within and 
betwen regions, having more than 80% explanative variables laying into Personal 
Income, Distance to Hospital, Available Beds, and Primary Care Ambulatory alterna-
tives. Other variables were not deemed to be significant.
PHP71
DIffEREnTIAL PRICIng fOR PHARmACEUTICALS: OvERvIEw Of A wIDELY 
DEbATED PRICIng COnCEPT AnD kEY CHALLEngES
Rémuzat C1, Tavella F2, Toumi M3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, London, UK, 3University of Marseille, Marseille, 
France
objeCtives: Differential pricing (DPR) is based on the economic concept of price 
discrimination. DPR is reported as a potential effective way to: (1) Improve access to 
medicines in lower income countries whilst maintaining welfare in higher income 
countries; (2) Preserve incentives for R&D through higher prices in high income 
countries. This study aimed to assess the current situation of DPR for pharmaceu-
ticals in the European Union (EU). Methods: A literature review was conducted 
in MEDLINE®, WHO, OECD, and EU Commission websites, complemented by a grey 
literature search. Key DPR principles were identified and current implementation 
challenges in the EU were assessed. Results: Ramsey (1927) developed a well-
known DPR theory stating that prices should differ across markets according to 
inverse relation to demand elasticity, with more price-sensitive users, (i.e. lower 
income countries) charged at a lower price than less-price sensitive users. Another 
approach to DPR proposed by Danzon et al. (2013), called “value-based differential 
pricing”, would be to have prices reflecting utilization in each country. DPR is highly 
discussed among national/EU institutions and industry given the differences in 
GDP per capita and price levels of EU countries. However, several challenges were 
reported to limit DPR implementation: (1) DPR scheme is based on average per capita 
income; (2) Manufacturers attempt to apply higher price in low income markets 
and lower price in high income markets; (3) Differential distribution margins; (5) 
Risk of parallel trade; (6) Use of external reference pricing (ERP) where prices and 
undisclosed rebates in high income countries drive high prices in lower income 
countries. ConClusions: DPR is widely debated to enhance access to innova-
tive expensive medicines in the low income market. However, DPR optimization 
requires wide coordination and interaction, between the countries and the industry 
to minimize various counteracting policies and initiatives.
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objeCtives: One of the most significant effects of economic crisis in Greece is the 
rising number of unemployed and uninsured citizens. A large percentage of the 
attempt to identify barriers to access. This study aims to investigate the factors 
that act as determinants of HSU for the Greek population, as well as highlight 
their evolution since 2006. Methods: The study was based on data collected by 
three cross-sectional health interview surveys conducted by the National School of 
Public Health, Athens, Greece, in 2006, 2011 and 2015 with representative national 
samples of 4003, 6569 and 2012 adults respectively. Respondents were asked to 
answer a series of questions on HSU and report their demographic characteris-
tics. Results: A significant decrease in the basic measures of HSU between 2006 
and 2015 was detected. In 2006, 74.6% of respondents answered that they had used 
a health service in the last 12 months, whereas in 2015 the corresponding figure 
was only 46.5%. There was a statistically significant association between HSU and 
gender of respondents, with females utilizing the services at a considerably higher 
rate (52.9%) than men (38.6%). The degree of non utilization health services was 
not changed substantially in these surveys, however the reasons for not using the 
services were found to change and brought up statistically significant associa-
tions with age, income and occupation of respondents. It is noteworthy that the 
percentage of population unable to access healthcare due to inability to pay was 
5.9%, 8.5% and 27.4% in 2006, 2011 and 2015 respectively. ConClusions: It is 
evident that demographic and socioeconomic determinants influence the HSU. 
The findings highlight the problem of social inequalities as a major issue of health 
policy.
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objeCtives: Access to medicines is usually given under the regulatory approvals and 
subsequent coverage decisions, after efficacy and safety have been proven by clinical 
trials. Recently, systems to enable exceptional early access have been explored to meet 
significant, unmet, and urgent medical needs for frontier medicines. In Japan, the 
Advanced Medical Care B system (AMCB) is already in operation. Two other systems, 
the Compassionate Use system (CU) and the Patient-Initiated Mixed-Care system 
(PIMC), are planned to start. The objective of this study is to understand the design and 
institutional positioning of these three systems, identifying opportunities for further 
improvements. Methods: A documentary research was conducted by analyzing 
government documents and the Diet Record. Results: For the AMCB system, the 
review board designates technologies that include the use of unapproved medicines 
or off-label indications, after requests from health care professionals. The CU sys-
tem is to be fully introduced in 2015 and targets medicines at later stages of clinical 
development, opening up opportunities for patients who are not eligible for the tri-
als. The PIMC system is to start in 2016 and focused on medicines or patients that 
are not covered by the other two systems. The three systems have no legal financial 
aid programs to cover the costs of experimental medicines, while the systems allow 
coverage of other treatment costs than those medicines. Details of the CU and PIMC 
systems are currently under discussion. ConClusions: The scopes of the three 
systems were found to be complementary to one another, covering both unapproved 
medicines and patients excluded from clinical studies. Legal financial aid would be 
worth considering for more equitable and extensive early access.
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objeCtives: China’s New Medical Reform (NMR), which started in 2009, aims at 
improving the equity of basic health service, especially in the less well-off areas. 
The purpose of this study is to know whether the popularity of NMR has allevi-
ate the existing health inequity in rural West China by comparing indicators of 
health equity of rural residents covered by New Rural Cooperative Medical System 
(NRCMS) before and after China’s NMR. Methods: Related data have been col-
lected respectively from 2860 and 2432 rural residents through random-sampling 
household questionnaire survey in Z County, Shaanxi, China, in November 2009 
(before NMR) and October 2012 (after NMR). The sample residents are divided 
into 5 groups by per capita annual income in families, and equity of health need, 
utilization and benefit have been calculated through Concentration Index (CI) and 
ANOVA. Results: On equity of health need, CIs for two-week morbidity and half-
year prevalence rate of chronic diseases among rural residents of different income 
levels in 2009 and 2012 are -0.0524, -0.0536 and -0.0792, -0.0840 respectively. On 
equity of health service utilization, CIs for treatment of two-week morbidity in 
2009 and 2012 are -0.0096 and -0.0992 respectively; CIs for hospitalization and non-
hospitalization of residents are 0.0032, -0.1712 and -0.0396, -0.1548 respectively. 
On benefit equity, CIs for hospitalization rate of residents in 2009 and 2012 are 
-0.0208 and -0.0712 respectively; CIs for average compensation of hospitaliza-
tion are -0.0212 and -0.1620 respectively. Difference in economic burden caused 
by diseases among residents of different income levels is non-significant after 
the implementation of NMR (P> 0.05). ConClusions: NMR has improved the 
equity of health service need of rural residents to some extent while reduced 
the utilization equity little. Benefit equity is enhanced since low-income resi-
dents benefit more than high-income counterparts from in-patient health service. 
Rural residents’ economic burden caused by diseases has reduced significantly 
after NMR.
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